Development of a methodology for in vivo follow-up of hepatocellular carcinoma in hepatocyte specific Trim24-null mice treated with myo-inositol trispyrophosphate.
Fiche publication
Date publication
septembre 2016
Journal
Journal of experimental & clinical cancer research : CR
Auteurs
Membres identifiés du Cancéropôle Est :
Dr LINDNER Véronique, Pr MARESCAUX Jacques, Dr TELETIN Marius
Tous les auteurs :
Ignat M, Akladios CY, Lindner V, Khetchoumian K, Teletin M, Muttter D, Aprahamian PM, Marescaux J
Lien Pubmed
Résumé
Genetically induced hepatocellular carcinoma (HCC) models are generally used to investigate carcinogenesis pathways, but very few attempts were made to valorize them for pharmacological testing. This study describes a micro-computed tomography (micro-CT) - based methodology for the diagnostic and lifelong follow-up of HCC in the hepatocyte-specific Trim24-null mouse line. Myo-inositol trispyrophosphate (ITPP) was tested as anti-cancer drug.
Référence
J. Exp. Clin. Cancer Res.. 2016 Sep;35(1):155